Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02998320 | Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis | PHASE3 | COMPLETED | 101 | — | — | Mar 10, 2017 | Sep 30, 2018 | Feb 15, 2019 | 16 | France |
| Arm | Type | Description |
|---|---|---|
| Genvoya | EXPERIMENTAL | Genvoya (E/C/F/TAF) Tablet (oral use) : 150/150/200/10 mg, one tablet each day for 28 days |
| Name | Type | Description |
|---|---|---|
| Genvoya | DRUG | Oral use (one tablet each day); 150/150/200/10 mg; 28 days |
Inclusion Criteria: * an age above 18 years * consultation within 48 hours following a risk of HIV transmission (blood or sexual contact) * indication for HIV post-exposure prophylaxis (according to French guidelines) * person able to understand the nature of the study * person who signed his conse...